Background: Gestational diabetes (GDM) affects up to 28% of pregnancies, depending on population and diagnostic criteria, with potential complications for mothers and babies. This overview summarises the evidence from Cochrane systematic reviews about interventions for preventing gestational diabetes mellitus and will provide an important resource for healthcare professionals caring for pregnant women, guideline developers, policy makers, researchers, and pregnant women at risk of developing GDM and their families.
Methods: Participants were healthy, nulliparous women recruited to the prospective SCOPE study between Nov 2004 and Feb 2011 in New Zealand, Australia, Ireland and United Kingdom. Women were assessed at 15AE1 weeks' gestation, where they were asked questions relating to use of drugs prior to and during pregnancy. Neonatal outcomes were analysed using multi variable linear or logistic regression, adjusting for confounders. Anthropometric outcomes (e.g. birth weight) were adjusted for gestational age at birth.
Results: Of 5610 women in the study, 314 (5.6%) reported any marijuana use in the 3 months prior to or during pregnancy. A large proportion (81%) of women quit marijuana either prior to (n=97) or during the first trimester (n = 157). The remaining 19% (n = 60) of marijuana users reported continued use during the 15 week SCOPE research visit. Continued use of marijuana in pregnancy was associated with significant reductions (adjusted mean difference; 95% CI) in infant gestation at birth (−7.9 days; 95%CI −7.9 to −3.9), birth weight (−113 g; −222 to −4), head circumference (−0.6 cm; −0.9 to −0.2), and birth length (−0.8 cm; −1.4 to −0.2), as well as an increased risk of severe neonatal morbidity or mortality (aOR 2.01; 1.06-3.82).
Discussion: Our results provide evidence supporting a negative impact of continued marijuana use during pregnancy on important neonatal outcomes independent of maternal cigarette smoking. The WHO endorses the administration of antenatal corticosteroids (ACS) in pregnant women at risk of preterm birth from 24 weeks to 34 weeks of gestation because it improves neonatal outcomes. However, this recommendation does not extend to women at risk of preterm delivery beyond 34 weeks, "the late preterm period", due to a paucity of safety literature for this cohort. Our aim was to study the risks and benefits of administering ACS in the late preterm gestation.
DOES ANTENATAL CORTICOSTEROID THERAPY IMPROVE NEONATAL OUTCOMES IN LATE-PRETERM
Methods: A retrospective cohort study was conducted on all singleton preterm deliveries from 34 to 36 6/7 weeks of gestation at the Northern Hospital from 2012 to 2017. Data was collected on ACS administration and neonatal outcomes. Univariate, multivariate and stratified analysis were carried out to compare the neonatal outcomes between mothers who received ACS and those who did not.
Results: 838 subjects were included in this study, comprising 228 subjects that received ACS and 610 that did not. Administration of ACS significantly reduced both the incidence of transient tachypnoea of the newborn (aOR=0.276, 95% CI 0.122-0.624) and the use of intermittent positive-pressure ventilation (aOR=0.617, 95% CI 0.387-0.987). We found no significant between-group differences in the incidence of respiratory distress syndrome, hypoglycaemia, jaundice requiring phototherapy, and admission to special care nursery.
Conclusions: Administration of ACS in late preterm birth was associated with a significant decrease in transient tachypnoea of the newborn and reduced requirement for intermittent positivepressure ventilation. There were no immediate adverse outcomes associated with ACS. 
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